OverviewSuggest Edit

Seelos Therapeutics is a clinical-stage bio-pharmaceutical company. It is focused on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system (CNS) disorders and in rare diseases. The Company’s portfolio includes several late-stage clinical assets targeting psychiatric and movement disorders, including orphan diseases.

TypePublic
Founded2016
HQNew York, US
Websiteseelostherapeutics.com

Latest Updates

Employees (est.) (Mar 2019)5(-54%)
Revenue (FY, 2019)$375 K
Share Price (Mar 2020)$0.5

Seelos Therapeutics Office Locations

Seelos Therapeutics has an office in New York
New York, US (HQ)
300 Park Ave
Show all (1)

Seelos Therapeutics Financials and Metrics

Seelos Therapeutics Revenue

Seelos Therapeutics's revenue was reported to be $375 k in FY, 2019
USD

Revenue (FY, 2019)

375.0k

Net income (FY, 2019)

(51.3m)

EBIT (FY, 2019)

(29.7m)

Market capitalization (26-Mar-2020)

23.3m

Closing stock price (26-Mar-2020)

0.5

Cash (31-Dec-2019)

10.3m
Seelos Therapeutics's current market capitalization is $23.3 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

4.1m8.4m2.5m9.3m4.8m5.8m511.0k375.0k

Cost of goods sold

378.7k324.0k23.0k918.0k922.0k511.0k

Gross profit

3.7m8.1m2.5m8.3m3.9m5.3m

Gross profit Margin, %

91%96%99%90%81%91%
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Revenue

1.6m799.4k781.5k119.6k5.2m1.2m28.0k5.5m1.9m475.0k462.0k1.3m626.0k464.0k4.3m375.0k

Cost of goods sold

1.0m115.2k76.4k83.8k119.2k702.0k15.0k75.0k485.0k233.0k509.0k142.0k233.0k93.0k111.0k

Gross profit

588.9k684.3k705.1k35.8k5.0m490.0k13.0k5.4m1.4m242.0k(47.0k)1.1m393.0k371.0k4.2m

Gross profit Margin, %

37%86%90%30%98%41%46%99%74%51%(10%)89%63%80%97%
USDY, 2019

Revenue/Employee

75.0k

Financial Leverage

-1.6 k x
Show all financial metrics

Seelos Therapeutics Online and Social Media Presence

Embed Graph

Seelos Therapeutics News and Updates

Seelos Therapeutics Receives Notice of Allowance for Composition of Matter Patent for SLS-007

Seelos Producing Viral Vectors and Preparing for In-Vivo Study in Parkinson's Disease Seelos Producing Viral Vectors and Preparing for In-Vivo Study in Parkinson's Disease

Seelos Therapeutics Announces Pricing of $5 Million Public Offering of Common Stock

NEW YORK, Feb. 10, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced today the pricing of an underwritten public offering of 6,666,6…

Seelos Therapeutics Announces Updates to SLS-005 (trehalose) Programs for Europe and U.S.

NEW YORK, Jan. 22, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced an update regarding its development programs for SLS-005 …

Seelos Therapeutics Announces Interim Data from Phase I Study of Intranasal Racemic Ketamine (SLS-002)

NEW YORK, Jan. 10, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced interim data from its Phase I study of Intranasal Racemic…

Seelos Therapeutics to Participate in 33rd Annual National MPS Society Family Conference

NEW YORK, Dec. 13, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it will participate in the 33rd Annual National MPS …

Seelos Therapeutics Announces Receipt of a Grant for Funding of SLS-005 Program

Team Sanfilippo Foundation to Provide Funding for Planned FDA/EMA Open-Label Phase IIb/III and Expanded Access Study in Sanfilippo Syndrome
Show more

Seelos Therapeutics Blogs

Archive Webcast of Seelos Presentation at Cowen’s 40th Annual Health Care Conference

On the morning of March 4, 2020 Dr. Raj Mehra presented at Cowen’s 40th Annual Health Care Conference in Boston, MA. The webcast link for this archived presentation is located at: http://wsw.com/webcast/cowen57/seel/

Seelos Therapeutics Frequently Asked Questions

  • When was Seelos Therapeutics founded?

    Seelos Therapeutics was founded in 2016.

  • How many employees does Seelos Therapeutics have?

    Seelos Therapeutics has 5 employees.

  • What is Seelos Therapeutics revenue?

    Latest Seelos Therapeutics annual revenue is $375 k.

  • What is Seelos Therapeutics revenue per employee?

    Latest Seelos Therapeutics revenue per employee is $75 k.

  • Who are Seelos Therapeutics competitors?

    Competitors of Seelos Therapeutics include GBT (Global Blood Therapeutics), Albireo Pharma and Melinta Therapeutics.

  • Where is Seelos Therapeutics headquarters?

    Seelos Therapeutics headquarters is located at 300 Park Ave, New York.

  • Where are Seelos Therapeutics offices?

    Seelos Therapeutics has an office in New York.

  • How many offices does Seelos Therapeutics have?

    Seelos Therapeutics has 1 office.